A retrospective study analysing short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children
Latest Information Update: 25 Nov 2020
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Graft-versus-host disease; Haemophagocytic lymphohistiocytosis
- Focus Therapeutic Use
- 25 Nov 2020 New trial record
- 01 Oct 2020 Results published in the International Journal of Hematology